Composition of oral solid medicine having good vivo behaviors

Abstract

The invention relates to a composition of an oral solid medicine having good vivo behaviors. The composition of the solid medicine has unit dosage forms and is measured with a releasing rate measuring method, and the release amounts of each unit dosage form are 15%-45%, 40%-80% and more than 80% of the labelled amount when the time period reaches one hour, four hours or eight hours respectively. The composition of the oral solid medicine can be applied to cerebrovascular diseases, improves brain metabolism and psychiatric symptoms, activates the respiratory activity of brain mitochondria, and improves brain energy metabolism of cerebral ischemia and the utilization rate of glucose inside the brain, so that the production of triphosadenine inside the brain is increased, the brain mitochondria are prevented from producing lipid peroxidase, and the membrane barrier caused by lipid peroxidation of a brain mitochondrial membrane and brain function damages caused by chronic cerebrovascular diseases, cerebral traumas and the like are prevented; and mental and behavioral disorders such as subjective symptoms, language barriers, dysphoria, depression, hypomnesia, mental decline and the like are improved.

Description

technical field [0001] The invention relates to an oral solid pharmaceutical composition with good behavior in vivo, which can be used for the treatment or prevention of nervous system diseases. Background technique [0002] Neuronal damage, neurodegenerative diseases and syndromes (Alzheimer's disease, multiple sclerosis, Friedrich's ataxia, brain and spinal cord injuries and neurotrauma, stroke, Parkinson's disease, alcoholism and narcolepsy, postoperative recovery syndrome and postanesthesia recovery syndrome) and many other conditions require effective treatment and prevention. [0003] Postoperative stroke and cognitive deficit (POSCD) syndrome is common, especially in older adults undergoing major surgical procedures such as heart surgery or hip replacement. In North America, more than 2.5 million such surgical procedures are performed each year, and the incidence of POSCD exceeds 30%. There is an urgent need for interventional therapy, and there are not enough treat...

AI Technical Summary

Problems solved by technology

Although this method is believed to reduce the first-pass effect of the drug, the rapid rise and fall of the drug concentration in the blood may require frequent dosing to keep the drug at the level of the therapeutic window for an extended period of time.

Images